[Skip to content]
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video

Dr Nathaniel Milton


Dr Nathaniel Milton
Contact Details
Dr Nathaniel Milton

Principal Lecturer

School of Clinical & Applied Sciences

0113 81 23612 N.G.Milton@leedsbeckett.ac.uk

About Dr Nathaniel Milton

Nat has an international reputation in the Alzheimer's Drug Discovery research field. He is a Fellow of the Royal Society of Biology and part of the Biomedical Sciences team in the School of Clinical & Applied Sciences.

For the past 20 years Nat has led the Amyloid-Binding Peptides research group, which conducts research into the biochemical interactions of amyloid peptides and their role in Alzheimer's disease, Diabetes, Creutzfeldt-Jakob disease and oxidative stress responses. He has used molecular biology, biochemical and cell biology techniques to discover and characterize the mechanisms of neuroprotection of a number of compounds. He has teaching experience, at both undergraduate and postgraduate levels, in the areas of Physiology, Pharmacology, Clinical Biochemistry, Neuroscience and Entrepreneurship.

Nat is and entrepreneur and has filed patent applications, which were taken to the intention to grant stage in Europe. He has founded an in silico based company, Neurodelta Ltd and raised government funding for commercial research in the Alzheimer’s Drug Discovery area.

Current Teaching

  • BSc and MSc Biomedical Sciences courses

Research Interests

The Amyloid-Binding Peptides research group is currently focused on the roles of endogenous cannabinoids and opioids in neuroprotection against toxic amyloid peptides. The group discovered neuroprotective properties of endocannabinoids against amyloid-ß in cell based models of Alzheimer's disease and has recently identified novel mechanisms of neuroprotection by endogenous cannabinoids.

The group has also shown that products of the KiSS-1 metastasis-suppressor gene, the Kisspeptin and Kissorphin peptides, specifically bind amyloid-ß, amylin plus prion protein peptides and are neuroprotective in vitro. KiSS-1 overexpression is also neuroprotective in vitro and acts via oxytocin/vasopressin and cyclooxygenase dependent mechanisms. The co-localization of Kisspeptin with amyloid-ß deposits in the pons region of Alzheimer's brain has recently been demonstrated. Co-localization of corticotropin-releasing hormone with amyloid-ß deposits and also co-localization of catalase with amyloid-ß deposits in the pons region of Alzheimer's brain has also been demonstrated.

Related News

Back to Top Button
Back to Top Button